TVTX · Travere Therapeutics, Inc. · Insider Trading

This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.

The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.

The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.

The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.

The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

This transaction represents a bona fide gift of 468 shares of common stock to a donor-advised fund. The reporting person authorized the gift on June 16, 2026, and the transfer occurred on June 22, 2026.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

The stock option is fully vested and exercisable.

This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

The equity award vests over a one year period.

This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.